Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

jcooptechit Apr. 29 at 4:04 PM

$CELZ 93% RESPONSE RATE… AND THE MARKET IS STILL ASLEEP ON THIS? CELZ recently dropped a game-changing update that could redefine regenerative medicine. 🧬 Ultrasome (derived from CELZ-201) ▪️ 93% response rate in knee osteoarthritis (pain + mobility improvement) ▪️ ZERO serious adverse events ▪️ Built from GMP-grade CELZ-201: strong platform continuity ▪️ Cell-free, off-the-shelf therapy = scalable + lower cost 💡 What This Means: This isn’t just a trial update… this is validation of a scalable regenerative platform ▪️ From cell therapy: mass-producible biologics ▪️ From niche treatment: commercial opportunity ▪️ Partnerships + expanded clinicals now in focus ⚠️ Knee osteoarthritis is a multi-billion dollar market with limited long-term solutions. 🔥 93% response. Clean safety. Scalable model. How long before the market prices this in??? Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $MESO $FATE $CAPR

1 · Reply

Goodstockday Apr. 28 at 2:27 PM

$FATE We should see a quarterly in the next 2 to 3 weeks. Hopefully, they will offer a little more early cancer treatment data. That is what holds the greatest potential to move this stock over the next few months.

1 · Reply

Jake140 Apr. 27 at 1:26 PM

$FATE Morning All! Back over $1.40 this week...hope so!

0 · Reply

AlphaOfBiotech Apr. 27 at 2:21 AM

$FATE The FY2025 report confirms a 100% strategic pivot to Autoimmune Diseases. First successful outpatient dosing of FT819 removes the massive cost barrier of hospital-based CAR-T. FDA approval for a single-arm registrational trial for Accelerated Approval is pending at any time. Redmile Group holds swaps with a reference price of $5.84, implying a 4 x revaluation is expected by the lead institutional holder with 14.9%. GO GO GO $FATE Best of luck to all of us🎉🎉🎉$KYTX and $ALLO

1 · Reply

WallStreetBuyDip Apr. 26 at 11:14 AM

$BNTX sitting at $105 with volume 48% below avg, while $FATE trading at $1 with volume 45% below avg - both Biotech plays. BNTX showing relative strength, but could sector catalysts change the game here?

0 · Reply

WestEgg Apr. 25 at 1:33 PM

$FATE new level of support here in the $1.30s. Comparing Fate to the recent buyout of Kelonia we would be have a $30 premium. Possible artificial short due to buyout talks. Anticipation for $1B-$3B price tag.

0 · Reply

None_ Apr. 24 at 11:48 PM

$FATE Upcoming at ASGCT: CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer https://pag.virtual-meeting.org/US/asgct2026/en-US/pag/presentation/686086

0 · Reply

None_ Apr. 24 at 11:47 PM

$FATE Upcoming at EULAR: Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge https://pag.virtual-meeting.org/EULAR/eular26/en-GB/pag/presentation/24303 Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning https://pag.virtual-meeting.org/EULAR/eular26/en-GB/pag/presentation/24009

0 · Reply

gata2016 Apr. 24 at 3:37 PM

$FATE Good news with the big guys coming in. This will double in the next year. Bank on it.

0 · Reply

Leogolas Apr. 24 at 12:58 PM

$FATE

1 · Reply

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 4:05 PM EDT - 27 days ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 9:20 AM EDT - 7 weeks ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 4:05 PM EST - 2 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 4:05 PM EST - 2 months ago

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 16, 2026, 1:00 PM EST - 2 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

IPSC

Dec 2, 2025, 9:00 AM EST - 5 months ago

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 5 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 5 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Oct 26, 2025, 11:30 AM EDT - 6 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Sep 4, 2025, 10:55 AM EDT - 8 months ago

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jun 11, 2025, 9:00 AM EDT - 11 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 11 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 1 year ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 9:25 AM EDT - 1 year ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 3, 2025, 11:50 AM EST - 1 year ago

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 4, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 19, 2024, 12:45 PM EDT - 1 year ago

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 2 years ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 12, 2024, 11:15 AM EDT - 2 years ago

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2023

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Sep 8, 2023, 9:30 AM EDT - 2 years ago

Fate Therapeutics Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Jun 13, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 3, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2023

May 3, 2023, 4:01 PM EDT - 3 years ago

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

Mar 21, 2023, 5:45 PM EDT - 3 years ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Mar 14, 2023, 3:05 PM EDT - 3 years ago

Fate Therapeutics Transcript: Barclays Global Healthcare Conference

Feb 28, 2023, 5:00 PM EST - 3 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2022

Feb 28, 2023, 4:01 PM EST - 3 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Feb 13, 2023, 8:00 AM EST - 3 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results

Nov 3, 2022, 5:00 PM EDT - 3 years ago

Fate Therapeutics Earnings Call Transcript: Q3 2022

Aug 3, 2022, 8:15 AM EDT - 4 years ago

Fate Therapeutics Earnings Call Transcript: Q2 2022

May 4, 2022, 5:57 AM EDT - 4 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2022

Feb 28, 2022, 5:25 AM EST - 4 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2021

Nov 15, 2021, 4:30 PM EST - 4 years ago

Fate Therapeutics Transcript: Investor Update

Nov 3, 2021, 8:00 PM EDT - 4 years ago

Fate Therapeutics Earnings Call Transcript: Q3 2021

Aug 19, 2021, 4:30 PM EDT - 5 years ago

Fate Therapeutics Transcript: Study Result

Aug 3, 2021, 6:31 PM EDT - 5 years ago

Fate Therapeutics Earnings Call Transcript: Q2 2021

Jun 2, 2021, 11:00 AM EDT - 5 years ago

Fate Therapeutics Transcript: AGM 2021

May 13, 2021, 5:00 PM EDT - 5 years ago

Fate Therapeutics Transcript: Study Result

May 5, 2021, 5:00 PM EDT - 5 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2021

jcooptechit Apr. 29 at 4:04 PM

1 · Reply

Goodstockday Apr. 28 at 2:27 PM

1 · Reply

Jake140 Apr. 27 at 1:26 PM

$FATE Morning All! Back over $1.40 this week...hope so!

0 · Reply

AlphaOfBiotech Apr. 27 at 2:21 AM

1 · Reply

WallStreetBuyDip Apr. 26 at 11:14 AM

0 · Reply

WestEgg Apr. 25 at 1:33 PM

0 · Reply

None_ Apr. 24 at 11:48 PM

0 · Reply

None_ Apr. 24 at 11:47 PM

0 · Reply

gata2016 Apr. 24 at 3:37 PM

$FATE Good news with the big guys coming in. This will double in the next year. Bank on it.

0 · Reply

Leogolas Apr. 24 at 12:58 PM

$FATE

1 · Reply

Jake140 Apr. 24 at 11:21 AM

$FATE Morning All! This company is a win-win! For the patients and the investors. Holding! Would like to even add more.

0 · Reply

StockDaddy68 Apr. 24 at 10:43 AM

$FATE TO THE MOON!

0 · Reply

Nik7777 Apr. 23 at 7:53 PM

$FATE 😴

0 · Reply

StockDaddy68 Apr. 23 at 2:04 PM

$FATE

0 · Reply

Nik7777 Apr. 23 at 1:34 PM

$FATE 🚀

0 · Reply

Jake140 Apr. 23 at 1:25 PM

$FATE

0 · Reply

gata2016 Apr. 23 at 1:22 PM

$FATE Fate Therapeutics (NASDAQ: FATE) is advancing its iPSC-derived CAR T-cell pipeline, notably focusing on FT819 for autoimmune diseases like lupus (SLE), which has shown sustained B-cell depletion and high safety, allowing for outpatient, same-day, no-conditioning treatment. The company has a cash runway into 2027 and is actively pursuing Phase 2 trials. CAR-T is big with companies like $CABA and $KYTX (I believe), both are 1st movers to the market, but you can see there is a clear path for these therapies for FATE.

0 · Reply

gata2016 Apr. 22 at 2:07 PM

$FATE I'm in. Invested a small started seed. @jacksparo you put me onto $SLS figured I would share

1 · Reply

Nik7777 Apr. 22 at 2:01 PM

$FATE 🚀

0 · Reply

StockDaddy68 Apr. 22 at 11:23 AM

$FATE I thought we were supposed to get news yesterday anyone know what's up?

0 · Reply

AlphaOfBiotech Apr. 22 at 2:45 AM

$FATE If an in vivo startup with zero human data can be worth multiple billion dollars, how much shoud $FATE $ALLO $CABA be re-evaluated? Buy $FATE so cheap while you still can. Wish us the best of luck & Cheers!

0 · Reply

radonco Apr. 21 at 7:40 PM

$FATE so Lilly bought in vivo car-t company for autoimmune diseases Orna Therapeutics in Feb for $2.4B and now bought in vivo car-t company for multiple myeloma Kelonia Therapeutics for $3.2B plus milestones! Fate’s pipeline covers what both of these companies are working on…Fate also lists in its pipeline a preclinical car-t targeting cd19/cd38/bcma/gprc5d which would likely prevent any antigen escape in multiple myeloma. Lilly is betting on in vivo but I think they should have just bought Fate!

1 · Reply

Market Cap	151.17M
Revenue (ttm)	6.65M
Net Income (ttm)	-136.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,049.92%
Debt to Equity Ratio	0.00

Volume	912,000
Avg Vol	1,457,478
Day's Range	N/A - N/A
Shares Out	116.28M
Stochastic %K	10%
Beta	2.23
Analysts	Sell
Price Target	$4.94